Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing a poster ...

Digital Customer Success Benchmark reveals a striking AI implementation crisis: while 72% of CS teams call AI "critical" by 2026, only 32% run even a single live use case, with just 3% achieving ...

Over two thirds of patients with hidradenitis suppurativa experience fewer flares, new lesions, and improved quality of life while using GLP-1 receptor agonists.

and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown ...

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced ...

Story May 29 - Stealth BioTherapeutics: After delays, Stealth said the FDA turned down its approval request but set out a path to accelerated approval, prompting the biotech to lay off 30% of its ...

Also just emerged from stealth mode is the cancer immunotherapy company VacV Biotherapeutics, which will use novel Vaccinia virus technology to target a range of cancers. Based out of Queen Mary ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

Stealth BioTherapeutics' filing for Barth syndrome therapy elamipretide has been turned down by the FDA, but there may be a way forward for the drug. At ASCO 2025, Realyze CEO Aaron Brauser talks ...